Clinical Trial Detail

NCT ID NCT03981614
Title Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

colorectal cancer

Therapies

trifluridine/tipiracil hydrochloride

Binimetinib + Palbociclib

Age Groups: adult senior

Additional content available in CKB BOOST